Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
Official title: 1/2 GLobal trial Of Bromocriptine for PeriPartum CardioMyopathy (GLOBal PPCM)
Funded at University of Alabama at Birmingham · NIH-11625553 · Data updated 2026-11-12
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2033 |
| Funding year | 2026 |
| Award (this year) | $31,320 |
| NIH project number | 3UG3HL177574-01A1SC |
| Project ID | NIH-11625553 on NIH RePORTER |
Who could benefit from this research
✓Could help
Postpartum women with peripartum cardiomyopathy who have started standard heart failure treatment and are willing to consider bromocriptine.
✕Less likely to help
Patients who do not have PPCM or who cannot take bromocriptine due to safety concerns may not benefit.
What this research studies
This trial enrolls 650 women recently after giving birth who have peripartum cardiomyopathy and will randomly receive bromocriptine or a placebo in addition to their usual heart failure therapy. It will take place at at least 18 sites across 15 low- and middle-income countries, with results checked six months after randomization. Safety for mothers and babies will be monitored closely, including how bromocriptine affects lactation.
Why it matters
Potential benefit: If successful, the therapy could reduce maternal death, improve heart function, or lower hospital readmissions after childbirth.
How similar studies have gone: Preliminary small studies and animal data suggest potential benefit, but a large-scale trial is required to confirm safety and efficacy.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Tita, Alan Thevenet N. — University of Alabama at Birmingham
- Study coordinator: Tita, Alan Thevenet N.
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
-
Bromocriptine Added to Standard Care for Postpartum Heart Muscle Disease (GLOBal PPCM)
A large international study will test whether adding the drug bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.